Press Releases


MOLOGEN AG with new major shareholder

SALVATOR Asset Management crosses 5-percent threshold

The Berlin-based biotechnology company MOLOGEN AG announced today that SALVATOR Asset Management (“Vermögensverwaltungs GmbH”) holds more than 5 percent of MOLOGEN shares. All shares were acquired through the stock exchange.

"We are highly convinced of the innovative potential of the company, that´s why we have decided to invest into MOLOGEN shares. With its unique technologies MOLOGEN is able to develop new therapies against severe diseases such as cancer or infections", said Ferdinand Jakob Count of Thun and Hohenstein, General Manager of SALVATOR Asset Management. "In the long-term, this potential will be reflected in the valuation of MOLOGEN."

"We are very delighted to have won this very experienced investor", said Dirk Simon, Chief Financial Officer of MOLOGEN AG. "The complete purchase of shares through the stock exchange is an impressive demonstration of the interest of SALVATOR in our company."


MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.

Disclaimer concerning prognoses
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

3 Questions to Dr. Söhngen

Dr. Mariola Söhngen CEO MOLOGEN AG

Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

[email protected]